For more than 50 years, U.S. academic medical centers (AMCs) have been the global engine for pharmaceutical innovation, dedicated to medical education, scientific research, and patient care.
Atech is building what it calls 'vibe-engineering' for hardware, a platform that lets users describe a physical device concept in natural language and receive a working prototype, with all underlying technical complexity handled by the platform.
"We're gearing up to go into the clinic," Isomorphic Labs president Max Jaderberg said on April 16 at WIRED Health in London. "It's going to be a very exciting moment as we go into clinical trials and start seeing the efficacy of these molecules."
We definitely look for AV experience. The reason is that AV was the first big application of physical AI, so people who have worked at AV companies have seen what it takes to ship complex physical AI at scale.
Amazon Bio Discovery enables scientists to run complex computational workflows through more than 40 AI-specialized foundational models, trained on a wide range of biological datasets. These models generate and evaluate potential drug molecules, alongside AI agents that help scientists to select models, optimize inputs and evaluate candidates according to their research.
The SFPD's Special Investigation Division took over the case and have since detained both 25-year-old Amanda Tom and 23-year-old Muhamad Tarik Hussein, seizing three firearms in the process with the help of a warrant.
DeepSeek V4 Pro has a total of 1.6 trillion parameters, making it the biggest open-weight model available, outstripping competitors like Moonshot AI's Kimi K 2.6 and MiniMax's M1.
Qi Sun's DrayEasy platform exemplifies a significant advancement in logistics, merging quoting, booking, and real-time tracking into a seamless automated experience for shippers.
Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.
Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
